Abstract: There has been a need for a neutralizing monoclonal antibody which is useful for antibody therapy effective against ebolavirus. The present invention provides a monoclonal antibody or an antigen-binding fragment thereof, which recognizes an internal fusion loop of ebolavirus GP and is capable of neutralizing the biological activity of ebolavirus.

Abstract: This application relates to an useful drug for prevention or treatment of avian influenza virus infection, and specifically provides a multiple antigen peptide comprising a dendritic core and 4-8 antigen peptides, wherein each of the antigen peptides is bound to a terminus of the dendritic core directly or through a spacer, and is a peptide consisting of 7-12 consecutive amino acids in the amino acid sequence of SEQ ID NO: 4, the multiple antigen peptide inducing the production of IgG antibodies in mammalian animals or birds, and further provides an immunity inducer comprising the multiple antigen peptide.

Abstract: This application provides: a multiple antigen peptide comprising a dendritic core and 4-8 antigen peptides, wherein each of the antigen peptides is bound to a terminus of the dendritic core directly or through a spacer and is a peptide consisting of 7-15 consecutive amino acids in the amino acid sequence of SEQ ID NO: 1, or a peptide which is the same as the peptide except that 1-3 amino acids are substituted; and an immune inducer comprising the multiple antigen peptide(s), wherein the multiple antigen peptide and the immune inducer are both useful for prevention or treatment of Ebola virus infection.

Abstract: There has been a need for a neutralizing monoclonal antibody which is useful for antibody therapy effective against ebolavirus. The present invention provides a monoclonal antibody or an antigen-binding fragment thereof, which recognizes an internal fusion loop of ebolavirus GP and is capable of neutralizing the biological activity of ebolavirus.